June 2021 Simoa® Publications: Alzheimer’s Disease
Effects of pre-analytical procedures on blood biomarkers for Alzheimer’s pathophysiology, glial activation, and neurodegeneration
Ashton NJ, et al.
Alzheimer’s & dementia (Amsterdam, Netherlands). 2021;13:e12168
Lower White Matter Volume and Worse Executive Functioning Reflected in Higher Levels of Plasma GFAP among Older Adults with and Without Cognitive Impairment
Asken BM, et al.
J Int Neuropsychol Soc. 2021:1-12
Longitudinal plasma phosphorylated tau 181 tracks disease progression in Alzheimer’s disease
Chen SD, et al.
Translational psychiatry. 2021;11:356
Plasma biomarkers of Alzheimer’s disease improve prediction of cognitive decline in cognitively unimpaired elderly populations
Cullen NC, et al.
Nature communications. 2021;12:3555
Detecting amyloid positivity in early Alzheimer’s disease using combinations of plasma Aβ42/Aβ40 and p-tau
Janelidze S, et al.
Alzheimer’s & dementia : the journal of the Alzheimer’s Association. 2021
ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer’s disease
Novak P, et al.
Nat Aging. 2021;1:521-534
Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measures
Palmqvist S, et al.
Nat Med. 2021 Jun;27(6):1034-1042
Plasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjects
Pereira JB, et al.
Brain. 2021 Jun 2;awab163
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease
Salloway S, et al.
Nature medicine. 2021
Development and validation of a high-sensitivity assay for measuring p217+tau in plasma
Triana-Baltzer G, et al.
Alzheimers Dement (Amst). 2021 May 27;13(1):e12204
June 2021 Simoa® Publications in Other Therapeutic Areas
